An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
E7080-G000-205 Ph1b
Study Overview
E7080
lenvatinib
NCT01136733, EU CTR 2010-019484-10
Aug 2010 - Jun 2014
Metastatic Renal Cell Carcinoma
Determine the DLTs, MTD and establish the recommended dose for Phase 2
The CSR synopses contained on this website are from clinical trials sponsored by Eisai and are provided for informational purposes only. These summaries contain data from the specific study population but do not include the patient-level data from each study participant. The results reported in any single trial may not reflect the overall potential risks or benefits associated with Eisai’s products.
Only health care professionals may determine if a specific product is appropriate as a treatment option for a particular patient. Health care professionals should refer to the specific labelling information approved in their country when making prescribing decisions.
The information provided is not intended to commercialize or promote Eisai’s products for any unapproved uses.
All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information contained on this website. Eisai reserves the right to amend any information on this website at any time at its sole discretion.
The clinical trial lay summaries contained on this website are from clinical trials sponsored by Eisai and are provided for informational purposes only. These summaries contain data from the specific study population but do not include the patient-level data from each study participant. The results reported in any single trial may not reflect the overall potential risks or benefits associated with Eisai’s products.
Only health care professionals may determine if a specific product is appropriate as a treatment option for a particular patient. Health care professionals should refer to the specific labelling information approved in their country when making prescribing decisions.
The information provided is not intended to commercialize or promote Eisai’s products for any unapproved uses.
All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information contained on this website. Eisai reserves the right to amend any information on this website at any time at its sole discretion.
If you have questions about the results, please speak with the doctor, research nurse, or other team member at your trial site.
By clicking “Accept” you are acknowledging that you have read and understood this statement.
Molina M et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol 2014 Jan; 73 (1):181-9. DOI: 10.1007/s00280-013-2339-y
Data Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
Redacted documents are available upon request for this study.